Back to New Jersey

S301 • 2026

Classifies 7 Hydroxymitragynine as Schedule I drug.

Classifies 7 Hydroxymitragynine as Schedule I drug.

Budget
Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Turner, Shirley K.
Last action
2026-03-16
Official status
Referred to Senate Budget and Appropriations Committee
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Classifies 7 Hydroxymitragynine as Schedule I drug.

Classifies 7 Hydroxymitragynine as Schedule I drug.

What This Bill Does

  • Classifies 7 Hydroxymitragynine as Schedule I drug.
  • Topic: Budget and Appropriations Fiscal note: This bill has been certified by OLS for a fiscal note.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-03-16 New Jersey Legislature

    Reported from Senate Committee, 2nd Reading

  2. 2026-03-16 New Jersey Legislature

    Referred to Senate Budget and Appropriations Committee

  3. 2026-01-13 New Jersey Legislature

    Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee

Official Summary Text

Classifies 7 Hydroxymitragynine as Schedule I drug.
Topic:
Budget and Appropriations
Fiscal note:
This bill has been certified by OLS for a fiscal note.

Current Bill Text

Read the full stored bill text
S301 TR

SENATE, No. 301

STATE OF NEW JERSEY

222nd LEGISLATURE

�

PRE-FILED FOR INTRODUCTION IN THE 2026 SESSION

Sponsored by:

Senator SHIRLEY K. TURNER

District 15 (Hunterdon and Mercer)

Senator� KRISTIN M. CORRADO

District 40 (Bergen, Essex and Passaic)

Co-Sponsored by:

Senator Tiver

SYNOPSIS

���� Classifies 7 Hydroxymitragynine as Schedule I drug.

CURRENT VERSION OF TEXT

���� As reported by the Senate Health, Human Services and
Senior Citizens Committee with technical review.

��

An Act

concerning the classification of drugs and
substances and amending P.L.1970, c.226.

����
Be It
Enacted
by the Senate and General Assembly of
the State of New Jersey:

���� 1.� Section 5 of P.L.1970,
c.226 (C.24:21-5) is amended to read as follows:

���� 5.� a.� Tests. The director
shall place a substance in Schedule I if he finds that the substance:� (1) has
high potential for abuse; and (2) has no accepted medical use in treatment in
the United States; or lacks accepted safety for use in treatment under medical
supervision.

���� b.��� The controlled dangerous
substances listed in this section are included in Schedule I, subject to any
revision and republishing by the director pursuant to subsection d. of section
3 of P.L.1970, c.226 (C.24:21-3), and except to the extent provided in any
other schedule.

���� c.���� Any of the following
opiates, including their isomers, esters, and ethers, unless specifically
excepted, whenever the existence of such isomers, esters, ethers and salts is
possible within the specific chemical designation:

���� (1)�� Acetylmethadol

���� (2)�� Allylprodine

���� (3)�� Alphacetylmethadol

���� (4)�� Alphameprodine

���� (5)�� Alphamethadol

���� (6)�� Benzethidine

���� (7)�� Betacetylmethadol

���� (8)�� Betameprodine

���� (9)�� Betamethadol

���� (10)� Betaprodine

���� (11)� Clonitazene

���� (12)� Dextromoramide

���� (13)� Dextrorphan

���� (14)� Diampromide

���� (15)� Diethylthiambutene

���� (16)� Dimenoxadol

���� (17)� Dimepheptanol

���� (18)� Dimethylthiambutene

���� (19)� Dioxaphetyl butyrate

���� (20)� Dipipanone

���� (21)� Ethylmethylthiambutene

���� (22)� Etonitazene

���� (23)� Etoxeridine

���� (24)� Furethidine

���� (25)� Hydroxypethidine

���� (26)� Ketobemidone

���� (27)� Levomoramide

���� (28)� Levophenacylmorphan

���� (29)� Morpheridine

���� (30)� Noracymethadol

���� (31)� Norlevorphanol

���� (32)� Normethadone

���� (33)� Norpipanone

���� (34)� Phenadoxone

���� (35)� Phenampromide

���� (36)� Phenomorphan

���� (37)� Phenoperidine

���� (38)� Piritramide

���� (39)� Proheptazine

���� (40)� Properidine

���� (41)� Racemoramide

���� (42)� Trimeperidine.

���� d.��� Any of the following
narcotic substances, their salts, isomers and salts of isomers, unless
specifically excepted, whenever the existence of such salts, isomers and salts
of isomers is possible within the specific chemical designation:

���� (1)�� Acetorphine

���� (2)�� Acetylcodone

���� (3)�� Acetyldihydrocodeine

���� (4)�� Benzylmorphine

���� (5)�� Codeine methylbromide

���� (6)�� Codeine-N-Oxide

���� (7)�� Cyprenorphine

���� (8)�� Desomorphine

���� (9)�� Dihydromorphine

���� (10)� Etorphine

���� (11)� Heroin

���� (12)� Hydromorphinol

���� (13)� Methyldesorphine

���� (14)� Methylhydromorphine

���� (15)� Morphine methylbromide

���� (16)� Morphine methylsulfonate

���� (17)� Morphine-N-Oxide

���� (18)� Myrophine

���� (19)� Nicocodeine

���� (20)� Nicomorphine

���� (21)� Normorphine

���� (22)� Phoclodine

���� (23)� Thebacon

����
(24)� 7 Hydroxymitragynine
.

���� e.���� Any material, compound,
mixture or preparation which contains any quantity of the following
hallucinogenic substances, their salts, isomers and salts of isomers, unless
specifically excepted, whenever the existence of such salts, isomers, and salts
of isomers is possible within the specific chemical designation:

���� (1)�� 3,4-methylenedioxy
amphetamine

���� (2)�� 5-methoxy-3,4-methylenedioxy
amphetamine

���� (3)�� 3,4,5-trimethoxy
amphetamine

���� (4)�� Bufotenine

���� (5)�� Diethyltryptamine

���� (6)�� Dimethyltryptamine

���� (7)�� 4-methyl-2,5-dimethoxylamphetamine

���� (8)�� Ibogaine

���� (9)�� Lysergic acid
diethylamide

���� (10)

Marijuana; except that on and after
the effective date of the "New Jersey Cannabis Regulatory, Enforcement
Assistance, and Marketplace Modernization Act," P.L.2021, c.16 (C.24:6I-31
et al.), marijuana shall no longer be included in Schedule I and shall not be
designated or rescheduled and included in any other schedule by the director
pursuant to the director's designation and rescheduling authority set forth in
section 3 of P.L.1970, c.226 (C.24:21-3).

���� (11)� Mescaline

���� (12)� Peyote

���� (13)� N-ethyl-3-piperidyl
benzilate

���� (14)� N-methyl-3-piperidyl
benzilate

���� (15)� Psilocybin

���� (16)� Psilocyn

���� (17)� Tetrahydrocannabinols,
including those produced by way of manufacture, except when found in hemp or a
hemp product cultivated, handled, processed, transported, or sold pursuant to
the "New Jersey Hemp Farming Act," P.L.2019, c.238 (C.4:28-6 et al.),
or cannabis or a cannabis item, as those terms are defined in section 3 of
P.L.2021, c.16 (C.24:6I-33), that is grown, cultivated, produced, manufactured,
or sold in accordance with the "New Jersey Cannabis Regulatory,
Enforcement Assistance, and Marketplace Modernization Act," P.L.2021, c.16
(C.24:6I-31 et al.).

(cf: P.L.2024, c.73, s.3)

���� 2.��� This act shall take
effect immediately.